This site uses cookies. By using this site you agree to receiving cookies. View Policy.

Successfully funded
Capital at risk
overfunded
genomes.io
287%
Raised
£143,630
Investors
287
Target
£50,000
Equity
8.74%
Pre-money valuation
£1,500,000

Aiming to resolve the problem of DNA data breach & exploitation by providing individual users with a technology to sequence, store, manage & commercialise their genomic data. We will help users to protect the most valuable piece of private information they will ever possess: their DNA data.

  • A tech start-up in the rapidly evolving Genome Management marketplace
  • A robust, decentralised, blockchain technology
  • An ambition to engage with pharmaceutical companies and research organisations
  • Giving individuals control over their DNA data

Idea

Sequencing of human genomes is rapidly becoming an affordable technology for general consumers.

The drop in operational costs for this technology, combined with the enormous potential for personalised medicine, means that we are looking at a future where all of humanity, all 7B+ people could have their genomes sequenced. The potential for exploitation of people’s personal genomic data is, therefore, a huge concern.

Securely storing genomes in a query-able way is an unrealised necessity that with blockchain technology is now realisable. Genomes.io aims to sequence 1 billion genomes and to provide private and secure B2C and B2B product services, such as our marketplace and store, on top of them. We are developing decentralised technology which uses proof of computations to perform queries on the human genome, without compromising any of the genomic sequence itself, safeguarding the data and privacy of our individual users at all times.

We have recently been acknowledged as 1 of the 5 hottest start-ups in Genome Data Management and received collaborative requests from a number of parties in the market.

We are raising a £50k investment to further advance our technology so our users are always able to safely manage their genomic data and to achieve our commercial objectives working as a Genome Data Management tool with partners in the Pharmaceutical and Research field.

THE MATERIALS YOU ARE SEEKING TO ACCESS ARE BEING MADE AVAILABLE BY THE COMPANY RAISING FINANCE AS IDENTIFIED ABOVE (THE "COMPANY") IN GOOD FAITH AND FOR INFORMATION PURPOSES ONLY AND SUBJECT TO THESE TERMS AND CONDITIONS.  CROWDCUBE CAPITAL LTD IS AUTHORISED BY THE FCA AND CARRIES OUT DUE DILIGENCE ON EACH COMPANY THAT LISTS ON CROWDCUBE AS SET OUT HERE.
 
This investment opportunity is not an offer to the public and is only available to registered members of Crowdcube.com who have qualified and categorised themselves as able to invest.  The investment opportunity is not directed at persons located in the United States, Canada or Japan. Any person resident outside the United Kingdom who wishes to view these materials must first satisfy themselves that they are not subject to any local requirements that prohibit or restrict access.
In particular, unless otherwise determined by the Company and permitted by applicable law and regulation, it is not intended, subject to certain exceptions, that any offering of the securities mentioned in such materials (the "Securities") by the Company would be made, or any documentation be sent in or into, the United States, Canada or Japan.  There will be no public offering of the Securities in the United States.
 
In order to access the pitch you must first become a qualifying member of Crowdcube on the basis of your status as either (i) self-certified ‘high net worth investor’, (ii) certified ‘sophisticated investor’, (iii) self-certified as a ‘sophisticated investor’ or (iv) certified as a ‘restricted investor’, in each case in accordance with the FCA’s Conduct of Business Sourcebook Chapter 4.7.  Potential investors are encouraged to "cross examine" the Company by interactive due diligence and use of the available online forums to bring the "wisdom of the crowd" to bear.  Accessing the pitch also means you agree to Crowdcube’s most recent website terms and conditions and investor terms and conditions, which include Crowdcube's limitation of liability.
 
If you are not permitted to view materials on this webpage or are in any doubt as to whether you are permitted to view these materials, please exit this webpage.  Crowdcube’s or the Issuer’s press announcements and this information page do not constitute an offer to sell securities of the Company.  Further, it does not constitute a recommendation by the Company, Crowdcube or any other party to sell or buy securities in the Company.
 
By registering or logging into Crowdcube.com to view the investment opportunity, you certify that you are legally entitled to view the investment opportunities, are an authorised investor and you agree to all applicable terms and conditions on this website, including this disclaimer.

To see the rest of the genomes.io pitch, join now.
It’s free, quick and easy.

Join

Already registered? Log in

To see the rest of the genomes.io pitch, join now.
It’s free, quick and easy.

genomes.io

Join to read more information about the genomes.io team, documents, and what other investors are saying about the pitch.

If you choose to invest we won’t take your money until the pitch closes and you can cancel your investment at any time.

Crowdcube is a leading investment crowdfunding platform

Successfully Invested
£689m+
Registered Investors
735k+